Literature DB >> 6842375

Esterase activities in adult rabbit eyes.

V H Lee.   

Abstract

The rational design of prodrugs to improve the therapeutic efficacy of existing drugs would be expedited if the nature of the in vivo enzymatic conditions that regenerate the drugs from their prodrugs is known. Using albino and pigmented rabbits as models, this research seeks to delineate the esterase activities in their corneas, irises, ciliary bodies, and aqueous humor, which are intimately involved in the disposition of drugs from topical dosing. This was achieved by monitoring the hydrolysis kinetics of alpha-naphthyl acetate, both in the presence and absence of esterase inhibitors, upon incubation with aqueous humor and homogenates of cornea, iris, and ciliary body. It was found that in both breeds of rabbits, esterase activity was the highest in the iris-ciliary body followed by the cornea and then the aqueous humor, and that multiple esterases probably existed in the aqueous humor, and the ocular tissues studied. However, the esterase activity in the cornea and iris-ciliary body of the pigmented rabbit was greater when compared with the albino rabbit. Based on these results, drugs and prodrugs containing ester linkages can undergo varying extents of esterase-mediated hydrolysis while permeating the cornea and upon entering the aqueous humor, iris, and ciliary body. Moreover, in view of the differences in esterase activity that exist between the albino and pigmented rabbits, it would be necessary to employ both breeds of rabbits in evaluating the rate and extent to which ocular ester prodrugs would be converted to their parent compounds.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6842375     DOI: 10.1002/jps.2600720310

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

Review 1.  Locally administered ocular corticosteroids: benefits and risks.

Authors:  Charles N J McGhee; Simon Dean; Helen Danesh-Meyer
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery.

Authors:  Abeer M Al-Ghananeem; Peter A Crooks
Journal:  Molecules       Date:  2007-03-08       Impact factor: 4.411

Review 3.  Novel strategies for anterior segment ocular drug delivery.

Authors:  Kishore Cholkar; Sulabh P Patel; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2012-12-05       Impact factor: 2.671

Review 4.  Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition.

Authors:  Mariko Nakano; Catherine M Lockhart; Edward J Kelly; Allan E Rettie
Journal:  Drug Metab Rev       Date:  2014-05-26       Impact factor: 4.518

5.  Ocular Drug Distribution and Safety of a Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in Rabbit.

Authors:  Kongnara Papangkorn; John W Higuchi; Balbir Brar; William I Higuchi
Journal:  J Ocul Pharmacol Ther       Date:  2018-02-12       Impact factor: 2.671

6.  [Esterase activity of human organotypic cornea construct (HCC) as in vitro model for permeation studies].

Authors:  L Meyer; J Bednarz; C C Müller-Goymann; S Reichl
Journal:  Ophthalmologe       Date:  2005-10       Impact factor: 1.059

7.  Prodrugs of 5-iodo-2'-deoxyuridine for enhanced ocular transport.

Authors:  M M Narurkar; A K Mitra
Journal:  Pharm Res       Date:  1989-10       Impact factor: 4.200

Review 8.  Clinical significance of esterases in man.

Authors:  F M Williams
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

9.  Carboxylic ester hydrolase activity in hairless and athymic nude mouse skin.

Authors:  M K Ghosh; A K Mitra
Journal:  Pharm Res       Date:  1990-03       Impact factor: 4.200

10.  Creation of nano eye-drops and effective drug delivery to the interior of the eye.

Authors:  Yoshikazu Ikuta; Shigenobu Aoyagi; Yuji Tanaka; Kota Sato; Satoshi Inada; Yoshitaka Koseki; Tsunenobu Onodera; Hidetoshi Oikawa; Hitoshi Kasai
Journal:  Sci Rep       Date:  2017-03-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.